Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365531 | 0.79 | ALDH1A1 (0.44) | IDO1LOXL2TSHRMAPTMEN1 | |
| SCHEMBL7358482 | 0.79 | CA2 (0.46) | IDO1TSHRMAPTMEN1KMT2A | |
| SCHEMBL3345536 | 0.77 | HTT (0.41) | ALDH1A1CYP2C19LMNA | |
| SCHEMBL27777352 | 0.73 | TSHR (0.47) | IDO1LOXL2TSHRMAPTMEN1 | |
| SCHEMBL6562489 | 0.73 | IDO1 (0.61) | IDO1LOXL2TSHRMAPTMEN1 | |
| SCHEMBL4410508 | 0.73 | TSHR (0.44) | IDO1LOXL2TSHRMAPTALDH1A1 | |
| SCHEMBL4587579 | 0.72 | CA2 (0.58) | IDO1LOXL2TSHRMEN1KMT2A | |
| SCHEMBL630790 | 0.72 | GLA (0.53) | MAPTKMT2AALDH1A1GAACYP2C19 | |
| SCHEMBL5396086 | 0.71 | TSHR (0.49) | IDO1LOXL2TSHRMAPTMEN1 | |
| SCHEMBL27765240 | 0.71 | LOXL2 (0.61) | IDO1LOXL2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | IDO1 1029/4885LOXL2 1004/4885TSHR 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.